Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5.7%

Autolus Therapeutics plc (NASDAQ:AUTL) shares fell 5.7% on Friday . The company traded as low as $3.13 and last traded at $3.14. 390,099 shares were traded during mid-day trading, a decline of 76% from the average session volume of 1,605,249 shares. The stock had previously closed at $3.33.

Analyst Ratings Changes

A number of equities analysts recently commented on AUTL shares. Truist Financial boosted their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, June 17th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Stock Performance

The firm has a market cap of $925.82 million, a price-to-earnings ratio of -2.92 and a beta of 2.02. The business has a fifty day moving average of $4.05 and a two-hundred day moving average of $5.32.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The business had revenue of $10.09 million during the quarter, compared to the consensus estimate of $50.00 million. During the same quarter last year, the business earned ($0.23) earnings per share. On average, equities research analysts forecast that Autolus Therapeutics plc will post -0.78 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $100,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $105,000. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the first quarter worth approximately $108,000. SG Americas Securities LLC purchased a new stake in Autolus Therapeutics in the 1st quarter worth approximately $127,000. Finally, EntryPoint Capital LLC raised its holdings in Autolus Therapeutics by 113.6% in the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after acquiring an additional 11,456 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.